Improving oral health communication in paediatric dentistry using intraoral scanners: a multicentre pilot study.

Eur Arch Paediatr DentApr 29, 2026 (epub)
Clinical ResearchPediatricsOpen access

S Schick, M A Schlenz, N Schulz-Weidner et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicentre randomized controlled trial evaluated the effectiveness of intraoral scanners (IOS) in enhancing oral health communication among 60 children aged 6-14 and their caregivers. The intervention group, which received verbal oral health instructions alongside IOS visualisation, demonstrated significantly higher comprehension scores (4.40 ± 1.61 vs. 3.33 ± 1.81; p = 0.019) compared to the control group.

Key findings

  • Children in the intervention group had higher comprehension scores (4.40 ± 1.61 vs. 3.33 ± 1.81; p = 0.019).
  • Caregivers in the intervention group scored higher in comprehension (5.03 ± 1.25 vs. 4.10 ± 1.37; p = 0.008).
  • Scanning was perceived as 'fun' (83.8%) and 'informative' (81.3%) by children.
  • 94.8% of children rated the dentist's explanation as clear.

Why it matters

Improving communication in paediatric dentistry is crucial for enhancing understanding and compliance among young patients and their caregivers. This study suggests that integrating technology like IOS can significantly aid in achieving better educational outcomes.

Source

Published in Eur Arch Paediatr Dent. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.